ClinicalTrials.gov
ClinicalTrials.gov Menu

Moderately Hypofractionated Conformal Radiation Combined With Cisplatin for Esophageal Squamous Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03660449
Recruitment Status : Recruiting
First Posted : September 6, 2018
Last Update Posted : September 10, 2018
Sponsor:
Information provided by (Responsible Party):
Hui Liu, Sun Yat-sen University

Brief Summary:
This Phase II randomized study is to determine the efficacy and toxicities of moderately hypofractionated conformal radiation combined With cisplatin for esophageal squamous cell carcinoma.

Condition or disease Intervention/treatment Phase
Esophageal Squamous Cell Carcinoma Combination Product: Moderately hypofractionated conformal radiation combined With cisplatin Phase 2

Detailed Description:

This Phase II randomized study is to determine the efficacy and toxicities of moderately hypofractionated conformal radiation combined With cisplatin for esophageal squamous cell carcinoma.

All patients will receive five cycles of weekly cisplatin (25mg/㎡), each of 1 day's duration, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV. The primary end point is progression-free survival, which is the time that passes from the first day of radiotherapy to the date on which disease progresses. Progression-free survival will be calculated and compared using the Kaplan-Meier method.Toxicities will be graded according to CTCAE v. 4.0.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Phase Ⅱ Study of Cisplatin Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma
Actual Study Start Date : August 2, 2018
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Arm Intervention/treatment
Experimental: Experiment
All patients will receive five cycles of weekly cisplatin (25mg/㎡), each of 1 day's duration, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
Combination Product: Moderately hypofractionated conformal radiation combined With cisplatin
All patients will receive five cycles of weekly cisplatin (25mg/㎡), each of 1 day's duration, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.




Primary Outcome Measures :
  1. Progression-Free Survival [ Time Frame: 3 years ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 3 years ]
  2. rate of grade 3-4 radiation esophagitis [ Time Frame: 1 year ]
  3. rate of grade 3-4 radiation pneumonitis [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed esophageal squamous cell carcinoma
  • Inoperable stage II-IVa (UICC 2002; sixth edition), confirmed by contrast enhanced computed tomography,endoscopic ultrasonography, barium esophagram, emission computed tomography and/or positron emission tomography/computed tomography.
  • Eastern Cooperative Oncology Group (ECOG) performance status 1-2
  • Estimated life expectancy of at least 12 weeks
  • Charlson comorbidity index.4
  • Adequate bone marrow function: white blood cells grade 0 or 1,absolute neutrophils grade 0 or 1, platelets grade 0, haemoglobin grade 0 or 1
  • Adequate renal function: creatinine grade 0 or 1
  • Adequate liver function: serum bilirubin grade 0 or 1, alanine aminotransferase and aspartate aminotransferase <2 times of the upper normal limit
  • Weight loss.15% during 6 months prior to diagnosis
  • Forced expiratory volume second.1L

Exclusion Criteria:

  • Prior history of malignancy, except for nonmelanoma skin carcinoma or cervical carcinoma in situ
  • Previous anti-tumor therapy, including surgery, chemotherapy or radiotherapy
  • Contraindication for chemotherapy or radiotherapy
  • Malignant pleural or pericardial effusion
  • Women in pregnancy or lactation period
  • Women who has the probability of pregnancy without contraception
  • Weight loss≥15% during 3 months prior to diagnosis
  • In other clinical trials within 30 days
  • Addicted in drugs or alcohol, AIDS patients
  • Uncontrollable seizure or psychotic patients without self-control ability
  • Severe allergy or idiosyncrasy
  • Not suitable for this study judged by researchers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03660449


Contacts
Contact: Bo Qiu, Ph.D +86-020-87343031 qiubo@sysucc.org.cn
Contact: Hui Liu, Ph.D +86-020-87343031 liuhui@sysucc.org.cn

Locations
China, Guangdong
Hui Liu Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Hui Liu, professor    +86-020-87343031    liuhui@sysucc.org.cn   
Sponsors and Collaborators
Sun Yat-sen University
Investigators
Principal Investigator: Hui Liu, Ph.D Sun Yat-sen University

Publications:

Responsible Party: Hui Liu, Professor, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT03660449     History of Changes
Other Study ID Numbers: GASTO-1045
First Posted: September 6, 2018    Key Record Dates
Last Update Posted: September 10, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hui Liu, Sun Yat-sen University:
Esophageal Squamous Cell Carcinoma
Hypofractionated Conformal Radiation
Cisplatin

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Cisplatin
Antineoplastic Agents